• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly: September 2007 Issue

CenterWatch Monthly: September 2007 Issue

September 17, 2007
CenterWatch Staff

Fraudulent Study Broker At-Large: Cherie Thibodeau

Cherie Thibodeau has posed as a study broker for the past six years, in between her three stints in California State Prison. Working under numerous aliases and nine Social Security numbers, she has bilked numerous investigative sites out of potentially hundreds of thousands of dollars. Cherie Thibodeau has preyed on new and experienced sites alike. Other sites that have not yet fallen victim to her study brokering scam need to learn the warning signs for a dishonest broker. Investigative sites can avoid working with Thibodeau and her ilk.

Abigail Alliance Heading to Supreme Court

Abigail Alliance for Better Access to Developmental Drugs lost its lawsuit against the FDA last month in the U.S. Court of Appeals for the D.C. Circuit. The alliance took the FDA to court to establish that terminally ill patients in this country have a Constitutional right to have access to experimental drugs after phase I. Abigail Alliance now plans to argue its case before the Supreme Court of the United States. Some industry observers believe that if the alliance wins, it will undermine the drug development process by making clinical trials in terminal ill-nesses impossible to recruit for. Although Abigail Alliance lost its latest suit, the organization has had a marked effect on the FDA's expanded access program.

Affymetrix Launches Collaborations in Cancer Research Program in Europe

Affymetrix has partnered with about 30 leading scientists from European cancer institutes, research centers and universities, from countries including Denmark, Finland, Germany, Italy, Spain, The Netherlands and UK, as part of its collaborations in Cancer Research Program. The alliance will mean that Affymetrix will partially fund select research projects.

Eye On: Diabetes

Nearly 21 million Americans have diabetes and about 41 million have pre-diabetes, according to data from the Centers for Disease Control and Prevention (CDC). About 90-95% of patients with diabetes have type 2 diabetes, with increased attendant risk of cardiovascular disease, stroke, high blood pressure, limb amputation, blindness, neuropathy damage and kidney failure. CenterWatch has identified a pipeline of 16 different drugs in various stages of development for diabetes treatment. Some of these are new insulin formulations, and others act via different mechanisms to lower blood glucose.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing